Inventor · disambiguated record
Michal L. Schwartzman
Also filed as: SCHWARTZMAN MICHAL · SCHWARTZMAN MICHAL L · SCHWARTZMAN MICHAL LANIADO
6 granted patents·4 pending applications·131 citations·filing 1988–2024
83Inventor score
Top patents by PatentIndex Score
10 records- 0184US2025032453A120-hete receptor (gpr75) antagonists and methods of useUNIV TEXAS·Filed 2024·Application pending·0 cites
- 0280US2024041831A120-hete receptor (gpr75) antagonists and methods of useUNIV TEXAS·Filed 2023·Application pending·0 cites
- 0379US11690825B220-HETE receptor (GPR75) antagonists and methods of useUNIV TEXAS·Filed 2017·Granted Jul 4, 2023·1 cites·28 claims
- 0476US4906467ANovel, long-duration treatment for glaucomaNEW YORK MEDICAL COLLEGE·Filed 1988·Granted Mar 6, 1990·49 cites·11 claims
- 0571US5102670AMethod for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levelsABRAHAM NADER G·Filed 1990·Granted Apr 7, 1992·49 cites·16 claims
- 0662US2023364192A1Modulation of beta cell regeneration through gpr75 signalingNEW YORK MEDICAL COLLEGE·Filed 2023·Application pending·0 cites
- 0756US6110472AVitamin B12 containing scalp and skin treatment compositionsHEMOGEN INC·Filed 1994·Granted Aug 29, 2000·22 cites·6 claims
- 0844US5674505AMethod for treating non-ocular epithelial disorders via increasing heme oxygenase levels and/or decreasing levels of arachidonic acid derivativesHEMOGEN INC·Filed 1994·Granted Oct 7, 1997·10 cites·12 claims
- 0935US2002151734A112-HETrE analogs and methods of use thereofFiled 2002·Application pending·0 cites
- 1025US5783201AMethod for treating non-ocular epithelial disorders via increasing heme oxygenase levels and/or decreasing levels of arachidonic acid derivativesHEMOGEN INC·Filed 1997·Granted Jul 21, 1998·0 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Michal L. Schwartzman files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →